Exercise

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Recommended Exercise Method...
• Exercise's Effects on the H...
• Exercise's Effects on Diabe...
• Exercise's Effects on Bones...
• Exercise's Effects on the L...
• Exercise's Effects on Weigh...
• Exercise's Effects on Other...
• Complications
• Motivation
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Chronic Conditions and Exercise:

• A new study found that aerobic and resistance training significantly reduced fatigue in men undergoing radiation treatments for prostate cancer. Fatigue is a common side effect of such treatments.
• Doctors at the Mayo Clinic found that exercise improves the physical and emotional well-being of patients with Alzheimer's disease. The patients exercised for as little as 60 minutes each week. - 1 Comment
  Read More ›

Diabetes - type 2

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Causes
• Risk Factors
• Symptoms
• Screening Tests
• Treatment
• Lifestyle Changes
• Medications
• Long-Term Complications
• Emergency Complications
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Drug Approvals

• Sitagliptin (Januvia), the first in a new class of diabetes drugs called DPP-4 inhibitors, was approved in 2006.
• Janumet, a 2-in-1 pill that contains both sitagliptin and metformin, was approved in 2007.
• These drugs are taken by mouth and may be more convenient for patients than exenatide (Byetta), a similar drug. DPP-4 inhibitors do not cause weight gain and may pose a lower risk for hypoglycemia than some other diabetes drugs.

Drug Safety Alert Rosiglitazone (Avandia) may significantly increase the risk for heart attack, indicates a review published in the Journal of the American Medical Association. In 2007, a panel of experts from the Food and Drug Administration (FDA) agreed the drug increases the risk of heart attacks -- but concluded it should remain on the market. - 4 Comments

Breast cancer

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Risk Factors
• Prevention and Lifestyle Fa...
• Symptoms
• Diagnosis
• Prognosis
• Treatment
• Surgery
• Radiation
• Medications
• Chemotherapy
• Hormone Therapy
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Drug Approvals

• In September 2007, Evista (raloxifene) was approved for prevention of breast cancer in postmenopausal women with osteoporosis, and postmenopausal women at high risk for invasive breast cancer. Raloxifene and tamoxifen are the only two drugs approved for breast cancer prevention in high-risk women.
• In March 2007, lapatinib (Tykerb) was approved in combination with capecitabine (Xeloda) for treatment of advanced HER2-positive breast cancer.
• In November 2006, trastuzumab (Herceptin) was approved for treatment of early-stage HER2-positive breast cancer. Trastuzumab is also approved for advanced HER2-positive breast cancer.

Screening

• The American College of Physicians’ 2007 guidelines recommend that women with a low risk for breast cancer talk to their doctor before starting to have mammogram screening at age 40. - 0 Comments
  Read More ›

Endometriosis

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Causes
• Symptoms
• Risk Factors
• Complications
• Diagnosis
• Treatment
• Lifestyle Changes
• Medications
• Conservative Surgery
• Hysterectomy
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Drug Approval Women with menstrual pain due to endometriosis have a new treatment option. In May 2007, the FDA approved Lybrel, a continuous-dose oral contraceptive that completely eliminates menstrual periods. Lybrel, which contains low doses of the estrogen estradiol and the progesterone levonorgestrol, is taken 365 days a year with active pills. - 0 Comments

Uterine fibroids and hysterectomy

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Causes
• Symptoms
• Risk Factors
• Complications
• Diagnosis
• Lifestyle Changes
• Medications
• Surgery
• Other Procedures
• Hysterectomy
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Uterine Artery Embolization Versus Standard Surgery Many women with fibroids are considering a procedure called uterine artery embolization (UAE) as an alternative to standard surgery such as hysterectomy or myomectomy. A study published in 2007 in the New England Journal of Medicine compared these treatment approaches. The study suggested that UAE results in shorter hospital stay and faster recovery time, but a small percentage of women may later need repeat embolization or a hysterectomy. - 0 Comments

Urinary incontinence

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Stress Incontinence
• Urge Incontinence
• Overflow Incontinence
• Functional Incontinence
• Risk Factors
• Diagnosis
• Prognosis
• Treatment
• Lifestyle Changes
• Other Treatments
• Behavioral Treatments
• Medications
• Surgery
• Other Procedures
• Catheters and Collection De...
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Sling Procedure Versus Burch Colposuspension The sling procedure is better than Burch colposuspension in treating stress incontinence but may cause more post-operative urinary complications, according to results from an important 2007 New England Journal of Medicine study. In the first large-scale clinical trial to directly compare these two types of surgery, 47% of women who underwent the sling procedure had no urinary incontinence 2 years after surgery, compared with 38% of women who received the Burch procedure. However, 63% of women who had the sling procedure (and 47% of women who underwent the Burch procedure) experienced urinary tract infections following surgery. - 0 Comments

Vasectomy and vasovasostomy

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Considerations
• Male Contraception
• Surgery
• Complications
• Unexpected Pregnancy
• Long-Term Complications
• Reversal Surgery
• Assisted Reproductive Techn...
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Search Continues for the "Male Pill" Research is progressing on a male contraceptive, but there have also been setbacks. The drug miglustat (Zavesca), which is used to treat a rare condition called Gaucher's disease, had shown success in animal studies but failed to work in a clinical trial, according to results published in 2007 in Human Reproduction. Researchers are now investigating an experimental drug, Adjudin (AF-2364), which disrupts sperm production. - 0 Comments

Depression

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Causes
• Risk Factors
• Complications of Depression...
• Diagnosis
• Treatment
• Antidepressants and Drug Tr...
• Psychotherapy
• Other Treatments
• Lifestyle Changes
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Drug Approval In 2007, the Food and Drug Administration (FDA) approved the atypical antipsychotic drug aripiprazole (Abilify) for treatment of major depression in adults. Aripiprazole is used for treatment of schizophrenia and bipolar disorder. For depression, it is used in combination with antidepressant drug therapy. - 5 Comments